Tirzepatide for Weight Loss
The first dual-action GIP/GLP-1 medication, delivering the highest weight loss in clinical trials.
Reviewed by GlobalGLP1 editorial team • Drug facts last checked August 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Jump to a section
Overview
Tirzepatide is the active ingredient in Mounjaro (for type 2 diabetes) and Zepbound (for weight loss). It is the first medication that targets two hunger hormones at once: GIP and GLP-1. By activating both, it produces stronger weight loss and blood sugar control than GLP-1-only medications like semaglutide at the doses the two have actually been compared at. In the largest clinical trial, people on the highest dose lost an average of 22.5% of their body weight. It beat Wegovy 2.4 mg in SURMOUNT-5, the only head-to-head trial of the two, though the newer 7.2 mg dose of Wegovy has never been tested against it.
Tirzepatide acts on two hormone receptors, GIP and GLP-1. Drugs in testing that add a third, glucagon, are sometimes called "GLP-3" in the news. What is a "GLP-3"?
How Tirzepatide Works
Tirzepatide works by activating two hormones your body already makes: GIP and GLP-1. Most older weight loss medications only target one. Together, these hormones tell your brain you are full, slow down how fast food leaves your stomach, help the pancreas release insulin after meals, and may improve how your body burns and stores fat. You take it as a once-weekly shot (belly, thigh, or upper arm). The dual-hormone approach is why tirzepatide tends to produce more weight loss than single-target drugs like semaglutide.
FDA Approval
Mounjaro
Type 2 diabetes mellitus
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
Zepbound
Chronic weight management
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
Zepbound
Moderate to severe obstructive sleep apnea in adults with obesity
10 mg or 15 mg weekly injection
How You Take It
The full dose build-up takes about 5 to 6 months. Many people get excellent results at 10 mg without needing the highest dose. Your doctor will adjust based on your weight loss, blood sugar, and how your stomach handles it.
How Much Weight You Can Lose
In the main weight loss trial, people on tirzepatide 15 mg lost an average of 22.5% of their body weight over 72 weeks (about 17 months). That 22.5% is estimated assuming everyone stayed on treatment. Counting everyone who started, including those who stopped early, the average was 20.9%. This matters when you compare drugs, because the usual headline figure for Wegovy, 14.9%, is the counting-everyone number. The fair pairings are 20.9% against 14.9%, or 22.5% against 16.9%. At 10 mg, the average was 21.4%. Over a third of people on the highest dose lost 25% or more. For a 200-pound person, 22.5% is roughly 45 pounds.
Blood sugar effect: 1.9 to 2.6 points (Mounjaro, for diabetes)
Side Effects
Common Side Effects
- Nausea (about 29% of users at the 15 mg dose in SURMOUNT-1; usually worst during dose increases and eases over time)
- Diarrhea (about 23% of users; typically mild and short-lived)
- Decreased appetite (common; this is part of how the drug works)
- Vomiting (about 13% of users; tends to drop off after the first month or two)
- Constipation (about 12% of users)
- Abdominal pain (about 10% of users; usually mild)
- Indigestion / upset stomach (about 9% of users)
- Injection site reactions (uncommon; mild redness near the shot)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, rodent studies)
- Hypoglycemia (with insulin or sulfonylureas)
- Severe GI events
- Allergic reactions including anaphylaxis
- Breathing food or liquid into the lungs during surgery under general anesthesia or deep sedation. These drugs slow the stomach down, so tell your surgeon, anesthetist and dentist that you take one before any planned procedure
- Worsening of diabetic eye disease in people with type 2 diabetes who already have retinopathy. The label asks for monitoring; this is not described as a risk for people without diabetes
Managing side effects: Similar pattern to semaglutide: stomach-related side effects show up most during the first few weeks and around dose increases, then ease as your body adjusts. The slow dose build-up exists for this reason. Eating smaller, more frequent meals and avoiding high-fat foods help. If vomiting is persistent or severe, contact your provider. They can slow or pause the dose escalation.
Tirzepatide Cost & Savings (2026)
Savings programs: Eli Lilly offers the Zepbound Savings Card (commercially insured patients may pay as low as $25/month) and sells Zepbound direct through LillyDirect Self Pay as a single-patient-use KwikPen or a 4-count single-dose vial: $299 at 2.5 mg, $399 at 5 mg, $499 at 7.5 mg and $699 at 10 mg and above for a 28-day supply.
Who Should Not Take Tirzepatide
- Personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to tirzepatide or any ingredient in the medication
- Pregnancy or planning to become pregnant (stop at least 1 month before conception)
- Severe stomach or intestinal disease
Heart Health
Two major trials studied tirzepatide's effect on the heart. SURPASS-CVOT (published late 2025) confirmed it is as safe for the heart as other diabetes medications, and showed a reduction in the combined risk of heart attack, stroke, and procedures like stenting. Separately, the SUMMIT trial (2024) found that people with obesity and heart failure who took tirzepatide had 38% fewer heart failure events and 56% fewer hospitalizations for heart failure compared to placebo.
What this means for you: Tirzepatide is confirmed safe for the heart. If you have obesity and heart failure, the SUMMIT results are especially relevant because they showed real reductions in hospitalizations, not just weight loss.
What to Expect, Month by Month
Noticeable decrease in hunger and food noise. Some patients report reduced cravings for high-calorie foods specifically.
Consistent weight loss begins during dose escalation. Average 3-5% body weight lost. Dual GIP/GLP-1 action accelerates early results.
Approaching maintenance dose (10-15 mg). Steady 1-2.5 lbs per week loss. Blood sugar improvements prominent.
Average 15-20% body weight lost. Dramatic improvements in metabolic health markers, blood pressure, and lipids.
Weight loss plateau at 20-22.5% average. Some patients achieve 25%+ loss. Maintenance phase with sustained metabolic benefits.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will likely reduce your insulin dose by 20 to 50% when starting tirzepatide, and may also lower your sulfonylurea dose.
Because tirzepatide slows digestion, pills you take by mouth may absorb differently. This is most noticeable during the first few months when dose changes are happening and stomach effects are strongest.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting or changing your tirzepatide dose.
The FDA label tells prescribers to advise anyone on birth control pills to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase. In testing, tirzepatide cut peak blood levels of the hormones in a combined pill by more than half. Tirzepatide may cause fetal harm. Methods that are not swallowed, such as the patch, ring, implant, injection or IUD, are not affected.
Special Situations
Do not use during pregnancy; the label says to stop as soon as a pregnancy is known. Unlike semaglutide, whose label sets a two-month gap before trying to conceive, the tirzepatide label sets no such period, so ask your prescriber how long to stop beforehand. Animal studies showed harm to the fetus at high doses.
No dose change needed at any level, including end-stage kidney disease, where blood levels of tirzepatide were unchanged. Still watch for dehydration from nausea and vomiting, which can worsen kidney function on its own.
No dose change needed at any level. Blood levels of tirzepatide did not change in people with liver impairment.
No dose change needed. The Zepbound trials included 226 people aged 65 or older, 13 of them 75 or older. Slower dose increases may help reduce stomach side effects in older adults.
Not yet FDA-approved for adolescents. Clinical trials in teens (SURMOUNT-TEENS) are in progress. Some doctors prescribe it off-label for teens with severe obesity.
What Happens If You Stop
In the SURMOUNT-4 trial, people who stopped tirzepatide after 36 weeks regained about two-thirds of the weight they had lost over the following year. People who stayed on it continued to lose weight. This is why most doctors recommend staying on treatment long-term if it is working.
How to make stopping easier: Building healthy eating habits and regular exercise while on the medication is the best insurance against regain. Some doctors are exploring lower maintenance doses to keep weight off at lower cost. Start planning your long-term approach before stopping.
Tirzepatide FAQs
Clinical trials suggest tirzepatide produces greater average weight loss (20-22.5%) compared to semaglutide (15-17%). However, individual responses vary. The SURPASS-2 trial directly compared Mounjaro to Ozempic and showed superior A1C reduction and weight loss with tirzepatide.
Both contain tirzepatide at the same doses. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved for chronic weight management. Your doctor will prescribe the appropriate one based on your diagnosis.
Appetite reduction typically begins within 1-2 weeks. Measurable weight loss usually starts after 4-8 weeks as doses escalate. Full weight loss effects develop over 12-18 months at the maintenance dose.
Yes. Zepbound is FDA-approved for weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related condition, regardless of diabetes status.
Tirzepatide is the only dual GIP/GLP-1 receptor agonist. By targeting both receptors, it provides enhanced metabolic benefits that single-target GLP-1 medications like semaglutide don't offer. This dual mechanism is believed to contribute to its superior efficacy.
Long-term data (3+ years) is still being collected. The SURMOUNT trials showed sustained weight loss over 72 weeks with continued use. Like semaglutide, weight regain is expected after discontinuation. Cardiovascular outcome trials are ongoing.
Find Clinics Offering Tirzepatide
Compare Tirzepatide providers by pricing, telehealth availability, and patient ratings.
Search Tirzepatide Clinics →Related Tirzepatide resources
Find Tirzepatide Clinics by State
Ready to start Tirzepatide?
Search our directory of 3,318 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
References
Every figure on this page comes from one of the following. Prescribing information is linked on DailyMed, which serves the current label rather than a snapshot of an old one. Trials are linked by DOI.
- Zepbound (tirzepatide) injection: prescribing information
- Mounjaro (tirzepatide) injection: prescribing information
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) The 72-week weight-loss trial behind the ~21-22.5% figures.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) The only head-to-head trial of the two, and the fairest comparison of them.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) 731 patients; the basis of the heart-failure figures.
Drug facts on this page last checked against these sources August 2026.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.